Reassessing B cell contributions in multiple sclerosis
There is growing recognition that B cell contributions to normal immune responses extend
well beyond their potential to become antibody-producing cells, including roles at the innate …
well beyond their potential to become antibody-producing cells, including roles at the innate …
Reviewing the significance of blood–brain barrier disruption in multiple sclerosis pathology and treatment
The disruption of blood–brain barrier (BBB) for multiple sclerosis (MS) pathogenesis has a
double effect: early on during the onset of the immune attack and later for the CNS self …
double effect: early on during the onset of the immune attack and later for the CNS self …
Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis
EA Mills, MA Ogrodnik, A Plave… - Frontiers in neurology, 2018 - frontiersin.org
Dimethyl fumarate (DMF) is an effective treatment option for relapsing–remitting multiple
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …
The CD8 T cell-Epstein-Barr virus-B cell trialogue: a central issue in multiple sclerosis pathogenesis
C Veroni, F Aloisi - Frontiers in immunology, 2021 - frontiersin.org
The cause and the pathogenic mechanisms leading to multiple sclerosis (MS), a chronic
inflammatory disease of the central nervous system (CNS), are still under scrutiny. During …
inflammatory disease of the central nervous system (CNS), are still under scrutiny. During …
B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans
AA Wang, F Luessi, T Neziraj, E Pössnecker… - Science Translational …, 2024 - science.org
Anti-CD20 therapy to deplete B cells is highly efficacious in preventing new white matter
lesions in patients with relapsing-remitting multiple sclerosis (RRMS), but its protective …
lesions in patients with relapsing-remitting multiple sclerosis (RRMS), but its protective …
Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: what do we know after 20 years of rituximab
In 1997, rituximab was the first monoclonal antibody clinically approved for the treatment of
cancer. Ten years later, progressive multifocal leukoencephalopathy (PML), until that time a …
cancer. Ten years later, progressive multifocal leukoencephalopathy (PML), until that time a …
IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis
C Lückel, F Picard, H Raifer… - Nature …, 2019 - nature.com
Abstract IL-17-producing CD8+ (Tc17) cells are enriched in active lesions of patients with
multiple sclerosis (MS), suggesting a role in the pathogenesis of autoimmunity. Here we …
multiple sclerosis (MS), suggesting a role in the pathogenesis of autoimmunity. Here we …
Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies
GM Diaz, R Hupperts, J Fraussen, V Somers - Autoimmunity reviews, 2018 - Elsevier
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous
system (CNS) in which demyelination and neurodegeneration occurs. The immune system …
system (CNS) in which demyelination and neurodegeneration occurs. The immune system …
The pharmacokinetics of fumaric acid esters reveal their in vivo effects
U Mrowietz, PJ Morrison, I Suhrkamp… - Trends in …, 2018 - cell.com
Fumaric acid ester-based drugs are used for the treatment of psoriasis and multiple
sclerosis. All licensed fumaric acid ester drugs contain dimethylfumarate (DMF) as the main …
sclerosis. All licensed fumaric acid ester drugs contain dimethylfumarate (DMF) as the main …
Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
Objective To assess functional changes in lymphocyte repertoire and subsequent clinical
implications during delayed-release dimethyl fumarate (DMF) treatment in patients with …
implications during delayed-release dimethyl fumarate (DMF) treatment in patients with …